Summary
AB3A Chart
Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD
SRPT jumps nearly 8% after Elevidys shows sustained motor gains and slower progression three years post-dose in the phase III EMBARK DMD study.
Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript
Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript
Sarepta Therapeutics Inc. (AB3A) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Sarepta Therapeutics Inc. ever had a stock split?
Sarepta Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Douglas S. Ingram CEO | XDUS Exchange | US8036071004 ISIN |
| US Country | 1,372 Employees | - Last Dividend | 12 Jul 2012 Last Split | 3 Jun 1997 IPO Date |
Overview
Sarepta Therapeutics, Inc. is a forefront commercial-stage biopharmaceutical entity devoted to pioneering RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities aimed at the treatment of rare diseases. Since its inception in 1980, the company has established itself as an innovator in the field, located in the renowned biotech hub of Cambridge, Massachusetts. Through strategic collaborations and license agreements with prestigious institutions like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, and universities such as Florida and Duke, as well as with dynamic biotech innovators like Dyno Therapeutics, Hansa Biopharma, Genethon, and StrideBio, Sarepta Therapeutics has pushed the boundaries of genetic medicine, focusing on diseases with significant unmet medical needs.
Products and Services
- EXONDYS 51 Injection
- VYONDYS 53
- AMONDYS 45
- ELEVIDYS
- SRP-5051
- SRP-9003
A groundbreaking therapy designed to treat Duchenne muscular dystrophy (Duchenne) in patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping. This therapy represents a beacon of hope for those affected by this rare genetic condition, offering a targeted approach to manage its progression.
Aimed specifically at Duchenne patients with a confirmed mutation of the dystrophin gene that can benefit from exon 53 skipping. VYONDYS 53 exemplifies the company's tailor-made approach to treating genetic disorders, addressing the needs of a specific subset of the Duchenne community.
This therapeutic solution serves the Duchenne community by targeting patients with specific confirmed mutations of the dystrophin gene. AMONDYS 45 represents Sarepta Therapeutics' commitment to expanding treatment options for those affected by Duchenne muscular dystrophy, emphasizing personalized healthcare solutions.
As an adeno-associated virus-based gene therapy, ELEVIDYS is focused on treating ambulatory pediatric patients aged 4 through 5 years with Duchenne, who have a confirmed mutation in the Duchenne gene. This gene therapy approach marks a significant advancement in treating genetic disorders, providing hope for younger patients and their families.
Sarepta is also at the frontier of developing next-generation treatments with SRP-5051, a peptide conjugated PMO (phosphorodiamidate morpholino oligomer) that specifically binds exon 51 of dystrophin pre-mRNA. This therapeutic development underscores the company's ongoing commitment to innovation in drug development and personalized medicine for Duchenne muscular dystrophy.
This gene therapy program is aimed at addressing limb-girdle muscular dystrophies (LGMD), another group of rare genetic disorders. Through SRP-9003, Sarepta Therapeutics is expanding its reach beyond Duchenne, demonstrating its broad commitment to tackling a wide range of rare genetic conditions.
